|
Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2). |
|
|
Honoraria - Agios; Baxalta; Merck; Seagen; Tolero Pharmaceuticals |
Research Funding - Celgene (Inst); Exelixis (Inst); Seagen (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Agios |
|
|
Honoraria - Agios; Daiichi Sankyo; Novartis |
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo; Novartis |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Agios; Celgene; Novartis; Pfizer |
Research Funding - Agios; Celgene; Constellation Pharmaceuticals; GlaxoSmithKline; Novartis; Seagen |
Travel, Accommodations, Expenses - Celgene; Pfizer |
|
|
Consulting or Advisory Role - Agios; Celgene; Novartis |
|
Travel, Accommodations, Expenses - Agios; Celgene |